Orthocell Limited announced the appointment of two senior executives to its leadership team. The appointments support the Company's global expansion and commercialisation activities for its regenerative medicine product portfolio, and most notably its nerve repair device, Remplir. Mr. Jim Piper, joining Orthocell as Chief Financial Officer (CFO), brings extensive experience in strategic finance and operational execution across ASX-listed and high-growth companies.
As CFO, Mr. Piper will oversee financial management and governance initiatives to maximise financial performance and shareholder value. In addition to his responsibilities as CFO, Mr. Piper will also oversee Investor Relations, Procurement, and Information Technology functions. Mr. Piper's prior experience includes senior financial roles at Pilbara Minerals, where he led financial planning and analysis for corporate, operations, capital and modelling functions across major planning cycles.
He also held a leadership role at global consulting firm Accenture within the CFO Strategy and Consulting practice, advising major organizations on financial transformation, performance optimisation, and digital initiatives. Prior to his career in finance, Mr. Piper was an accomplished professional athlete. He represented Australia as a member of the swimming team at the 2004 Athens Olympic Games and won two gold medals at the 2002 Commonwealth Games.
He will commence employment with Orthocell on 1 August 2025. Mr. Piper will undertake the role as CFO after Ms. Nicole Telford's over 15-year tenure, during which time she played a pivotal role in the establishment and expansion of Orthocell's finance function, and its impressive growth curve. Ms. Telford commenced as Company Accountant, progressed to Financial Controller and was ultimately appointed CFO during her time with Orthocell.
She will be available as a part time advisor for up to six months to ensure a smooth transition.
